68Ga标记的DOTA-伊班膦酸盐（68Ga-DOTA-IBA）正电子发射断层扫描/计算机断层扫描（PET/CT）是一种新型骨靶向成像示踪剂，是一种有前途的骨转移检测诊断方法。因此，本研究旨在比较 68Ga-DOTA-IBA PET/CT 与 99mTc-MDP 全身骨扫描 (WBBS) 用于检测乳腺癌 (BC) 骨转移。在这项前瞻性研究中，45 名 BC 女性接受了影像学检查通过 68Ga-DOTA-IBA PET/CT 和 99mTc-MDP WBBS。记录临床和人口统计信息以及 BC 成像特征。比较两种方法的骨转移检出率和病灶数量。45名女性，年龄53.5±11.0岁。 68Ga-DOTA-IBA PET/CT骨转移检出率为100%（45/45），99mTc-MDP WBBS骨转移检出率为95.6%（43/45）。共检测出546个骨转移病灶。 68Ga-DOTA-IBA PET/CT 的病灶检出率为 100%（546/546），99mTc-MDP WBBS 的病灶检出率为 67.8%（370/546）。通过 68Ga-DOTA-IBA 在每个部位发现的病灶比通过 99mTc-MDP WBBS 多。68Ga-DOTA-IBA PET/CT 是比 99mTc-MDP WBBS 更灵敏的方法来评估 BC 骨转移，因此可能是一种有用的方法。骨转移的成像技术，同时为 BC 的 177Lu-DOTA-IBA 诊断和治疗反应评估提供视觉基础。有必要使用更广泛的研究队列进行进一步验证，以证实这些发现。https://www.chictr.org.cn/showproj.html?proj=170163，标识符 ChiCTR2200064487。版权所有 © 2024 Xiang，Zhang，Tan，Yan，Liu，马和陈。

68Ga labeled DOTA-Ibandronate (68Ga-DOTA-IBA) positron emission tomography/computed tomography (PET/CT), is a novel bone-targeting imaging tracer and promising diagnostic method for bone metastases detection. Therefore, this study aimed to compare 68Ga-DOTA-IBA PET/CT to the 99mTc-MDP whole-body bone scan (WBBS) for detecting bone metastases in breast cancer (BC).In this prospective study, 45 women with BC underwent imaging via 68Ga-DOTA-IBA PET/CT and 99mTc-MDP WBBS. Clinical and demographic information as well as BC imaging features were recorded. The two methods were compared in terms of their detection rate for bone metastases and the number of lesions.The 45 women were aged 53.5 ± 11.0 years. The bone metastases detection rate with 68Ga-DOTA-IBA PET/CT was 100% (45/45) and with 99mTc-MDP WBBS was 95.6% (43/45). A total of 546 bone metastases lesions were detected. The lesion detection rate using 68Ga-DOTA-IBA PET/CT was 100% (546/546) and using 99mTc-MDP WBBS was 67.8% (370/546). More lesions were found at each site via 68Ga-DOTA-IBA than via 99mTc-MDP WBBS.68Ga-DOTA-IBA PET/CT is a more sensitive method than 99mTc-MDP WBBS for assessing bone metastases in BC and may therefore represent a useful imaging technique for bone metastases, while offering a visual basis for 177Lu-DOTA-IBA diagnosis and therapy response assessments for BC. Further validation using a broader study cohort is warranted to confirm these findings.https://www.chictr.org.cn/showproj.html?proj=170163, identifier ChiCTR2200064487.Copyright © 2024 Xiang, Zhang, Tan, Yan, Liu, Ma and Chen.